Centre for Pulmonary Hypertension, University Medical Centre Hamburg - Eppendorf, 20246 Hamburg, Germany.
BMC Pulm Med. 2011 May 23;11:30. doi: 10.1186/1471-2466-11-30.
Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib.
Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect.At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing.
We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.
肺动脉高压（PH）是一种预后不良的危及生命的疾病。人们一直在努力针对疾病的主要血管增生方面进行治疗。有前途的新兴治疗方法是酪氨酸激酶抑制剂，如伊马替尼。
在这里，我们讨论了以前发表的病例的相关性，并增加了另一个特征明确的患者，该患者在长期接受多酪氨酸激酶抑制剂达沙替尼治疗（批准用于治疗慢性髓性白血病（CML）和费城染色体阳性急性淋巴细胞白血病）后发展为毛细血管前 PH（所有患者接受达沙替尼治疗的平均时间：26 个月）。因此，我们讨论了达沙替尼本身在长期治疗后导致 PH 的可能性，并引起了专家对这种可能的严重副作用的关注。目前，达沙替尼相关性 PH 的真实发病率仍不清楚，缺乏有关血流动力学的系统数据。
因此，我们建议对接受达沙替尼治疗的患者进行系统性筛查，以检测肺动脉高压，并随后收集血流动力学数据。
